Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OIG supplement report

This article was originally published in The Tan Sheet

Executive Summary

Office of the Inspector General draft report on effectiveness of dietary supplement claims, warnings for the elderly due out this summer, HHS division says; draft originally was expected by end of 2001. Report will be second supplement-related review conducted by OIG; office released findings on FDA's supplement adverse event reporting system roughly a year ago (1"The Tan Sheet" April 23, 2001, pp. 3-6)...

You may also be interested in...



CFSAN/Poison Control Center Supplement AER Contract Recommended By OIG

The American Association of Poison Control Centers has received numerous dietary supplement adverse event reports that would be useful to FDA, an April 19 HHS Office of Inspector General report on dietary supplement AERs states.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

Topics

UsernamePublicRestriction

Register

PS093948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel